GlassScriptPhysician profile
Cesar Rangel
NPI 1649965732
$799.51
in general payments reported to CMS, 2019-2025
8 companies · $637 in 2025
The $637 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $162 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $283.87 | 2025 | Austedo Xr |
| Viiv Healthcare Company | $150.68 | 2025 | Dovato, Apretude |
| Acadia Pharmaceuticals INC | $142.86 | 2024-2025 | Nuplazid |
| Gilead Sciences, INC. | $121.84 | 2025 | Yeztugo |
| Merck Sharp & Dohme LLC | $52.61 | 2024-2025 | Pifeltro, Capvaxive, Delstrigo |
| Averitas Pharma INC. | $17.75 | 2024 | Qutenza |
| Organon LLC | $15.15 | 2024 | |
| Dexcom, INC. | $14.75 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Rangel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.